Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncor bladder cancer test trial to begin in late summer, JHU researcher says.

This article was originally published in The Gray Sheet

Executive Summary

ONCOR BLADDER CANCER DIAGNOSTIC CLINICAL TRIAL TO BEGIN AT JOHNS HOPKINS in the late summer to assess the utility of a new molecular diagnostic test, according to Johns Hopkins University investigator David Sidransky, who developed the test. Under the direction of JHU principal investigator Mark Schoenberg, the Phase II/III trial will enroll 300 patients and assess whether the test can diagnose bladder cancer earlier than the standard diagnostic procedures -- cytology, or testing cancer cells in the urine, and cystoscopy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel